Clinical Chart Review, Part 1: Assessing and Managing the Patient with Bipolar Mania
neuroscienceCME Chart Review
Premiere Date: Monday, March 15, 2010This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, March 15, 2011
Note: Credit Is No Longer Available
 | Roger S. McIntyre, MD, FRCPC (Moderator) University of Toronto University Health Network Toronto, ON Chairman and Executive Director, Brain and Cognition, Depression and Bipolar Support Alliance (DBSA) Chicago, IL Clinical Professor, Department of Psychiatry and Neurosciences University of California School of Medicine Riverside, CA |
 | Terence A. Ketter, MD Professor of Psychiatry and Behavioral Sciences Founder and Chief, Bipolar Disorders Clinic Stanford University School of Medicine Stanford, CA |
| Amit Anand, MD (Content/Peer Reviewer) Professor of Psychiatry and Radiology Indiana University Bloomington, IN |
Optimal management of bipolar disorder begins with accurate diagnosis. The Depression and Bipolar Alliance reported that the misdiagnosis rate is 67% for bipolar patients with the most common misdiagnoses being unipolar depression (60%), anxiety disorder (26%), schizophrenia (18%), and borderline or antisocial personality disorder (17%).(1) When diagnosis is inaccurate or delayed, initial therapy is not properly derived or promptly delivered. In this series of neuroscienceCME Chart Reviews, the faculty will take participants through a series of patient cases focusing on assessment, treatment, and treatment adherence to improve the long-term management of patients with bipolar disorder. Faculty will engage participants in the discussion and development of best practice tips to apply in practice.
- Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-174.
To implement strategies to improve assessment, treatment selection, and long-term outcomes in patients with bipolar mania.
At the end of this CE activity, participants should be able to:
- Utilize validated tools to assess for mania symptoms in patients diagnosed with depression.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe validated tools used to assess the symptoms of mania and hypomania.
Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge educational grants from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc., and from Pfizer Inc. in support of this CE activity.
Physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other healthcare professionals interested in mental health.
CME Credit (Physicians):
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
(Live activity) This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
It has been assigned approval code 82RJY5-10. 0.5 contact hours will be awarded upon successful completion.
(Archive activity) This continuing nursing education activity was approved by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
It has been assigned approval code 82RKG8-10. 0.5 contact hours will be awarded upon successful completion.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.5 contact hours (0.05 CEUs)
Universal Program Number:
376-999-10-007-L01-P (live presentation)
376-999-10-007-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab�requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
Disclosure Declaration
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Indiana University School of Medicine (IUSM) and CME Outfitters, LLC, (CMEO) must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in activities sponsored by IUSM and CMEO are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Note: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
Dr. McIntyre has disclosed that he receives grants/research support from Eli Lilly and Company, Janssen-Ortho, Inc., and Shire Pharmaceuticals, as well as Private Industries or Non-Profit Funds: Stanley Medical Research Institute, National Alliance for Research on Schizophrenia and Depression (NARSAD). He serves on the advisory boards of AstraZeneca Pharmaceuticals LP, Biovail Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, France Foundation, GlaxoSmithKline, Janssen-Ortho, Inc., H. Lundbeck A/S, Organon, Pfizer Inc., Schering-Plough Corporation, Shire Pharmaceuticals, and Solvay/Wyeth. He serves on the speakers bureaus of AstraZeneca Pharmaceuticals LP, Biovail Pharmaceuticals, Inc., Eli Lilly and Company, Janssen-Ortho, Inc., H. Lundbeck A/S, Schering-Plough Corporation, and Wyeth Pharmaceuticals.
Dr. Ketter has disclosed that he receives grant support from Abbott Laboratories, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon Inc., Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc., Repligen Corporation, and Wyeth Pharmaceuticals. He serves as a consultant to Abbott Laboratories, Inc., AstraZeneca Pharmaceuticals LP, Astellas Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals Products, LP, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Organon International Inc., a part of Schering-Plough Corp, Sepracor, Inc., Solvay Pharmaceuticals, Inc., Valeant Pharmaceuticals, Vanda Pharmaceuticals, Wyeth Pharmaceuticals, and XenoPort, Inc. He has received lecture honoraria from Abbott Laboratories, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Noven Pharmaceuticals, Otsuka Pharmaceuticals, and Pfizer Inc.
Dr. Anand has disclosed that he has received honoraria from Pfizer Inc. as a consultant, and has received research grants from Eli Lilly and Company and AstraZeneca Pharmaceuticals LP as an independent investigator.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Indiana University School of Medicine, CME Outfitters, LLC, the faculty, Bristol-Myers Squibb Company, Otsuka America Pharmaceutical, Inc., and Pfizer Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
CR-001-031510-99
